Navigation Links
Anadys in Medical News

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...bott Diagnostics, Achillion Pharmaceuticals, Inc., anadys Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, ...agnostics Rights from Siemens Healthcare II-63 anadys Secures FDA Fast Track Designation for its Lead Dr...cation for Novel Hepatitis C to with FDA II-68 anadys Discontinues ANA975 II-68 Cerus Bags NIH Fundi...

Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering

...e sale of shares of its common stock and warrants. anadys estimates that net proceeds from the offering will... related expenses payable to the placement agent). anadys has entered into subscription agreements with each...er, solicitation or sale is unlawful. About anadys ...

Anadys Pharmaceuticals to Present at the Citi Biotech Day

... SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and an update on its ANA598 clinical program in he...l be available through April 15, 2009. About anadys ...

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights

... SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a clinica...3. For the twelve months ended December 31, 2008, anadys reported a net loss of $32.4 million, compared to ...onal oral non-nucleoside polymerase inhibitor that anadys is developing for the treatment of chronic hepatit...

Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results

... SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...2009, after the U.S. financial markets close. anadys will hold a conference call and webcast to discuss...l be available through March 12, 2009. About anadys ...

Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference

... SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and an update on its clinical programs: ANA598 an...e available through February 23, 2009. About anadys ...

Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study

... SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...nding doses of ANA598 over a period of three days. anadys expects to enroll approximately 30 patients in the...om all three cohorts in the first quarter of 2009. anadys may elect to explore other dose levels of ANA598 a...

Anadys Pharmaceuticals to Present at Bio Investor Forum

... SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and an update on its development programs. The p...ilable through November 13, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...

Isis Reports Financial Results and Highlights for Fiscal year 2007

... as President and Chief Executive Officer of Regulus. Dr. Xanthopoulos is the co-founder and former President and Chief Executive Officer of anadys Pharmaceuticals, Inc. * Peter S. Linsley, Ph.D., was appointed as Chief Scientific Officer of Regulus. Dr. Linsley was Executive Directo...

Anadys Pharmaceuticals to Present at BIO InvestorForum 2007

... SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t... Pharmaceuticals, Inc. will present an overview of anadys and an update on its two development-stage product...nd will be archived until October 24, 2007. About anadys ...
Anadys in Medical Technology

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

... SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno... standard of care." ANA598 Program Update anadys continues to make progress on all aspects of the A...l sites. 14 Day Healthy Volunteer Study anadys recently completed dosing healthy volunteers in a ...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

... SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno...d in the second cohort (400 mg bid) of the study. anadys expects to report detailed data from multiple coho...h other anti-HCV agents." About ANA598 anadys retains worldwide rights to ANA598, which was full...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

...ASLD SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t... have the Potential to Overcome Viral Resistance", anadys will present the results of in vitro studies that ... ANA598 in the Chimpanzee Model of HCV Infection", anadys will present data showing that ANA598 exhibits a s...

Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

... SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and its three clinical programs: ANA598 and ANA773...ailable through October 21, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

...LD SAN DIEGO, Sept. 24 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t... http://www.aasld.org . ANA598 Program Update anadys is now finalizing preparations to begin a Phase Ib...rts, eight on active treatment and two on placebo. anadys expects to have viral load data from all three coh...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

... PDT SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ery-other-day dosing over 28 days in HCV patients. anadys also continues to enroll patients in a separate Ph...elopment of ANA975. Webcast of Conference Call anadys will host a conference call today, July 7, 2008 at...

Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598

...is C SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...cessful completion of the healthy volunteer study, anadys plans to begin a Phase Ib study of ANA598 in HCV-i...nts in February and this study of ANA598 underway, anadys is now focused on achieving important clinical mil...

Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research

... SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) presented a...iple other anti-HCV agents, regardless of class. anadys also presented the pharmacokinetic (PK) profile of...direct antivirals." About ANA598 In June 2007, anadys announced the nomination of ANA598 as a clinical d...

Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection

...vivo SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced p...eatment of chronic HCV infection." In June 2007, anadys announced the nomination of ANA598 as a clinical d...ith hepatitis C virus infection." About Anadys anadys Pharmaceuticals, Inc. is a biopharmaceutical compa...

Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses

...es SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) presented p...redictor of potential clinical utility." In June, anadys announced the nomination of ANA598 as a clinical d...patients with hepatitis C virus infection." About anadys ...
Anadys in Biological News

Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference

... SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its clinical programs: ANA598 and ANA773 in he...ll be available through March 2, 2009. About anadys ...
Anadys in Biological Technology

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno... a number of clinical sites in the United States. anadys expects to receive 28-day safety and response (RVR...n-nucleoside inhibitor of the HCV RNA polymerase. anadys has completed three Phase I clinical studies of AN...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biophar...ly. For the six months ended June 30, 2009, anadys reported a net loss of $15.3 million, compared to ...osed Registered Direct Financing. In early June, anadys closed a "registered direct" offering through the ...

Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results

... SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ..., after the U.S. financial markets close. anadys will hold a conference call and webcast on Thursda...available through August 13, 2009. About anadys ...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno...ts in ongoing studies in hepatitis C and oncology, anadys intends to manage the ANA773 programs as potential...ge the tremendous effort and commitment of all our anadys colleagues, especially those whose positions have ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biophar...onal oral non-nucleoside polymerase inhibitor that anadys is developing for the treatment of chronic hepatit...Potent Antiviral Activity in HCV. Earlier today, anadys presented antiviral and safety data from all three...

Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results

... SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...2009, after the U.S. financial markets close. anadys will hold a conference call and webcast on Thursda...will be available through May 7, 2009. About anadys ...

Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry

... SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its clinical programs: ANA598 and ANA773 in he...l be available through April 16, 2009. About anadys ...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

... SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today anno... hepatitis C non-nucleoside polymerase inhibitor. anadys is currently enrolling patients in a Phase Ib stud...tment regimens." About ANA598 anadys recently initiated patient dosing in a Phase Ib st...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

... SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ...ive Officer of Anadys, will provide an overview of anadys and its three clinical programs: ANA598 and ANA77...ailable through December 17, 2008. About anadys ...

Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference

... SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced t...ive Officer of Anadys, will present an overview of anadys and its three clinical programs: ANA598 and ANA773...ailable through December 4, 2008. About Anadys anadys Pharmaceuticals, Inc. is a clinical-stage biopharm...
Other Tags
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
(Date:12/22/2014)... -- The 2014 Holiday Season may be the brightest ... Intelligence reports that the long anticipated floodgates for ... that intensifying demand for smart phones, tablets, and ... a global market of 2.5 billion users with ... According to Maxine Most , ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
Other Contents